 It's 9.20 here at Northwest News Radio. Here's your money update from Nicole Murray. Novo Nordisk and Eli Lilly shares have slid after Roche announced promising early stage trial data from its latest obesity drug. Roche said it's experimental. One's daily pill showed average weight loss of just over 6% in four weeks. The results come as competition mounts in the fast-growing weight loss drug sector, with Roche's pill likely to provide an appealing alternative for patients who dislike injections.